Offers Korean biopharmas technology to produce drugs, vaccines and biosimilars for global market
PBS Biotech, a US developer of single-use bioreactors for the biotechnology market, has signed an exclusive distribution agreement in Korea with Green Cross Medical Sciences (GCMS), a division of Green Cross Corporation and one of region’s largest pharmaceutical firms.
GCMS will market, sell and support PBS Biotech single-use bioreactors for use in r&d and production in the Korean drug, vaccine and biosimilar industry.
The Korean biopharma industry, now ranked the 12th largest in the world and 4th largest in Asia, aims to become a major global supplier within the next two decades. Today, the country’s pharmaceutical revenues are in excess of US$20bn with 8% coming from biotech.
‘We believe the PBS single-use bioreactor systems will be a significant and cost-effective contributor in helping the industry meet the drug and vaccine needs of our own population and for international customers,’ said Seung-Sam Seo, president of GCMS.
PBS Biotech bioreactors, which employ a low shear Air Wheel mixing mechanism, are used in developing plant, animal and insect cell cultures in lab, clinical, seed train and production uses. They work with popular industry probes, sensors and analytic devices and perfusion systems including Refine Technology.
The PBS bioreactors range from 3-litre bench-top units to 80-litre stand-alone systems. The company says it will be announcing larger-scale units in the months ahead.
All disposable bags and systems use USP Class VI materials.
PBS Biotech is headquartered in Camarillo, CA.